JP2022512900A5 - - Google Patents
Info
- Publication number
- JP2022512900A5 JP2022512900A5 JP2021523897A JP2021523897A JP2022512900A5 JP 2022512900 A5 JP2022512900 A5 JP 2022512900A5 JP 2021523897 A JP2021523897 A JP 2021523897A JP 2021523897 A JP2021523897 A JP 2021523897A JP 2022512900 A5 JP2022512900 A5 JP 2022512900A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862754934P | 2018-11-02 | 2018-11-02 | |
| US62/754,934 | 2018-11-02 | ||
| PCT/US2019/059401 WO2020092907A1 (en) | 2018-11-02 | 2019-11-01 | Acetylation writer inhibitor development and uses thereof |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022512900A JP2022512900A (ja) | 2022-02-07 |
| JPWO2020092907A5 JPWO2020092907A5 (https=) | 2022-11-08 |
| JP2022512900A5 true JP2022512900A5 (https=) | 2022-11-08 |
| JP7712867B2 JP7712867B2 (ja) | 2025-07-24 |
Family
ID=70463920
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021523897A Active JP7712867B2 (ja) | 2018-11-02 | 2019-11-01 | アセチル化ライター阻害剤の開発およびその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US12428412B2 (https=) |
| EP (1) | EP3873898B1 (https=) |
| JP (1) | JP7712867B2 (https=) |
| CN (1) | CN112969696B (https=) |
| AU (1) | AU2019371400B2 (https=) |
| CA (1) | CA3118597A1 (https=) |
| ES (1) | ES3038078T3 (https=) |
| WO (1) | WO2020092907A1 (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| CN111217802B (zh) * | 2018-11-27 | 2021-10-08 | 海创药业股份有限公司 | 一类组蛋白乙酰化酶p300抑制剂及其用途 |
| JP7623943B2 (ja) | 2018-11-30 | 2025-01-29 | カイメラ セラピューティクス， インコーポレイテッド | Ｉｒａｋ分解剤およびそれらの使用 |
| CN113646002A (zh) * | 2019-02-27 | 2021-11-12 | 上海睿跃生物科技有限公司 | 环amp反应元件结合蛋白(cbp)和/或300kda腺病毒e1a结合蛋白(p300)降解化合物和使用方法 |
| AU2020295399B2 (en) * | 2019-06-18 | 2025-10-16 | Dana-Farber Cancer Institute, Inc. | Small molecule target bromo/acetyl proteins and uses thereof |
| BR112021026517A2 (pt) | 2019-06-28 | 2022-05-10 | Kymera Therapeutics Inc | Degradadores de irak e usos dos mesmos |
| WO2021011868A1 (en) | 2019-07-17 | 2021-01-21 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| US12551564B2 (en) | 2019-12-10 | 2026-02-17 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
| WO2021127190A1 (en) | 2019-12-17 | 2021-06-24 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| US11857535B2 (en) | 2020-07-30 | 2024-01-02 | Kymera Therapeutics, Inc. | Methods of treating mutant lymphomas |
| US20240100170A1 (en) * | 2020-08-27 | 2024-03-28 | Cullgen (Shanghai), Inc. | Cyclic-amp response element binding protein (cbp) and/or adenoviral e1a binding protein of 300 kda (p300) degradation compounds and methods of use |
| US20240122941A1 (en) * | 2020-12-25 | 2024-04-18 | National Cancer Center | Therapy based on synthetic lethality in swi/snf complex-dysfunction cancer |
| PH12023500015A1 (en) | 2020-12-30 | 2024-03-11 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| JP2024509887A (ja) * | 2021-03-09 | 2024-03-05 | ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド | Ｅｐ３００分解剤および神経芽細胞腫におけるその使用 |
| US12187744B2 (en) | 2021-10-29 | 2025-01-07 | Kymera Therapeutics, Inc. | IRAK4 degraders and synthesis thereof |
| WO2023125476A1 (zh) * | 2021-12-30 | 2023-07-06 | 成都先导药物开发股份有限公司 | 螺环化合物及其双功能化合物和用途 |
| EP4472967A4 (en) | 2022-01-31 | 2026-04-15 | Kymera Therapeutics Inc | Iraqi Degradation Agents and Their Uses |
| GB202209404D0 (en) * | 2022-06-27 | 2022-08-10 | Univ Of Sussex | Compounds |
| JP2025137900A (ja) * | 2022-08-10 | 2025-09-25 | 住友ファーマ株式会社 | 第４級炭素で置換された３級アミド誘導体 |
| KR20250025759A (ko) * | 2022-09-07 | 2025-02-24 | 히트젠 주식회사 | 스피로 화합물 및 용도 |
| CN119255996B (zh) * | 2022-09-08 | 2026-04-24 | 成都先导药物开发股份有限公司 | 螺环化合物及其用途 |
| WO2024064358A1 (en) * | 2022-09-23 | 2024-03-28 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| IL319486A (en) | 2022-10-07 | 2025-05-01 | Pfizer | HSD17B13 Inhibitors and/or Retarders |
| KR20250117453A (ko) | 2022-12-16 | 2025-08-04 | 화이자 인코포레이티드 | 3-플루오로-4-하이드록시벤즈아미드-함유 억제제 및/또는 분해제 및 이의 용도 |
| CN116178339B (zh) * | 2023-02-20 | 2024-08-06 | 杭州医学院 | 以含氧烷烃为连接链的hdac降解剂及其制备方法和应用 |
| GB202302941D0 (en) | 2023-02-28 | 2023-04-12 | Tocris Cookson Ltd | Proteolysis-targeting chimeras |
| US20250188030A1 (en) | 2023-12-07 | 2025-06-12 | Pfizer Inc. | Biphenyl and Phenylpyridine Compounds |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| EP2755482B1 (en) | 2011-09-15 | 2016-06-01 | Merck Sharp & Dohme Corp. | Combination of mk-1775 and mk-8776 for treating cancer |
| US20160235716A1 (en) * | 2014-09-18 | 2016-08-18 | Abbvie Inc. | Spirocyclic hat inhibitors and methods for their use |
| GB201519196D0 (en) | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP Receptor Antagonists |
| AU2016349781A1 (en) | 2015-11-02 | 2018-05-10 | Yale University | Proteolysis targeting chimera compounds and methods of preparing and using same |
| EP3454862B1 (en) * | 2016-05-10 | 2024-09-11 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
| CN109641874A (zh) * | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
| EP3532464A4 (en) * | 2016-10-28 | 2020-07-08 | Icahn School of Medicine at Mount Sinai | COMPOSITIONS AND METHODS FOR THE TREATMENT OF EZH2 MEDIATION CANCER |
| IL315310A (en) * | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| AU2020295399B2 (en) * | 2019-06-18 | 2025-10-16 | Dana-Farber Cancer Institute, Inc. | Small molecule target bromo/acetyl proteins and uses thereof |
-
2019
- 2019-11-01 JP JP2021523897A patent/JP7712867B2/ja active Active
- 2019-11-01 WO PCT/US2019/059401 patent/WO2020092907A1/en not_active Ceased
- 2019-11-01 CA CA3118597A patent/CA3118597A1/en active Pending
- 2019-11-01 AU AU2019371400A patent/AU2019371400B2/en active Active
- 2019-11-01 ES ES19878099T patent/ES3038078T3/es active Active
- 2019-11-01 EP EP19878099.1A patent/EP3873898B1/en active Active
- 2019-11-01 US US17/289,662 patent/US12428412B2/en active Active
- 2019-11-01 CN CN201980072584.4A patent/CN112969696B/zh active Active
-
2025
- 2025-07-08 US US19/262,282 patent/US20250333402A1/en active Pending